Keyvantage Wealth’s Boston Scientific BSX Stock Holding History

Keyvantage Wealth’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,603	Closed	-$679K	–	96
2024 Q4	$679K	Buy	+7,603	New	+$669K	0.49%	37

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Keyvantage Wealth's BSX Position: Q1 2025 in Review

Keyvantage Wealth sold out of Boston Scientific (BSX) in Q1 2025, closing a stake of 7,603 shares — an estimated $679K sold.

Keyvantage Wealth first reported a position in BSX in Q4 2024 and held it in 1 quarter. The position peaked at $679K in Q4 2024. 1,642 funds tracked by Wall St. Rank hold BSX as of Q1 2025.

Keyvantage Wealth reported no remaining Boston Scientific position as of Q1 2025 after selling out during the quarter.
Keyvantage Wealth sold 7,603 Boston Scientific shares in Q1 2025, an estimated $679K.
Keyvantage Wealth first reported a position in Boston Scientific in Q4 2024 and held it in 1 quarter.
Keyvantage Wealth's Boston Scientific position peaked at $679K in Q4 2024.
1,642 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2025.

Based on Keyvantage Wealth's 13F filing for Q1 2025, filed 7 May 2025.